Will Other States Follow NY, Calif., in Taking On DTC Genetic-Testing Firms? | GenomeWeb
With politically influential California and New York taking a hard line against certain direct-to-consumer genetic-testing companies, the nascent personal genomics industry has been left to wonder what other states might do.
“Historically, many states look to New York and California for guidance,” Navigenics CEO Mari Baker told Pharmacogenomics Reporter this week. “I am sure they are following what is happening in those two states. It would be a shame if every state acted separately.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.

Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.

According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.

National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.